HOME>News & Media>LATUDA Press Room
Healthy bodies, healthy lives

On June 28, 2013, the U.S. Food and Drug Administration approved Latuda® (lurasidone HCl) for the treatment of adult patients with depressive episodes associated with bipolar I disorder (bipolar depression), both as monotherapy and as an adjunct to lithium or valproate.

Bipolar Depression Fact Sheet

 

 Date  Title
6/28/13 Sunovion Pharmaceuticals Inc. Announces FDA Approval of Latuda® (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Bipolar Depression
5/21/13 Sunovion Pharmaceuticals Inc. Presents Data Showing 12 Months of Latuda® (lurasidone HCl) Treatment Resulted in Higher Remission Rates in Adult Patients with Schizophrenia Compared to Seroquel XR® (quetiapine XR)
5/20/13 Sunovion Pharmaceuticals Inc. Announces Data Showing Latuda® (lurasidone HCl) was Associated with Low Rates of Weight and Metabolic Changes in Patients with Depressive Episodes Associated with Bipolar I Disorder
10/30/12 Sunovion Pharmaceuticals Inc. Announces FDA Acceptance of Two Supplemental New Drug Applications for the Use of Latuda® (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Depressive Episodes Associated with Bipolar I Disorder
09/06/12 Sunovion Pharmaceuticals Files Two Supplemental New Drug Applications Seeking Approval for the use of Latuda® (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Depressive Episodes Associated with Bipolar I Disorder
05/09/12 New Study Shows Patients Can Effectively be Switched to Latuda® (lurasidone HCl) from Other Antipsychotic Agents
05/07/12 Dainippon Sumitomo Pharma Co. Reports that Latuda (lurasidone HCl) Met Primary and Key Secondary Endpoints in Two Phase III Trials in Bipolar I Depression
05/05/12 Latuda® (lurasidone HCl) Label Updated With Expanded Dosing Range Providing Added Flexibility for the Treatment of Patients with Schizophrenia
10/27/11 LATUDA® (lurasidone HCl) Shown to be Non-Inferior to SEROQUEL XR® (quetiapine fumarate XR) in Risk for Relapse in a 12-Month, Double-Blind Extension Study of Adult Patients with Schizophrenia
05/17/11 Latuda® (lurasidone HCl) was Associated with Low Rates of Weight Gain and Metabolic Changes in Patients with Schizophrenia in Data Presented at the 164th Meeting of the American Psychiatric Association
02/03/11 Once-daily Latuda® (lurasidone HCl) Now Available in Pharmacies Nationwide for the Treatment of Patients with Schizophrenia
12/08/10 Latuda® (lurasidone HCl) Significantly Improves Symptoms of Schizophrenia in Fifth Positive Placebo-Controlled Study
10/28/10 FDA approves once-daily LATUDA® (lurasidone HCl) for the treatment of patients with schizophrenia

Corporate Communications
508-357-7740
84 Waterford Drive
Marlborough, MA 01752
communications@sunovion.com